|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
|
FI4005592T3
(fi)
|
2010-07-06 |
2023-01-13 |
|
Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
|
|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PL4008357T3
(pl)
|
2010-08-31 |
2023-03-06 |
Glaxosmithkline Biologicals Sa |
Małe liposomy do dostarczania rna kodującego immunogen
|
|
PT3981427T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
RS63430B1
(sr)
|
2010-10-01 |
2022-08-31 |
Modernatx Inc |
Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
|
|
TR201903651T4
(tr)
*
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
CA3107288A1
(en)
|
2011-06-08 |
2012-12-13 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
|
EP2729165B1
(en)
*
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK3682905T3
(da)
|
2011-10-03 |
2022-02-28 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
|
|
DE12858350T1
(de)
|
2011-12-16 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte mrna zusammensetzungen
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
HK1206601A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
ES2753138T3
(es)
*
|
2012-07-06 |
2020-04-07 |
Glaxosmithkline Biologicals Sa |
Complejos de proteínas de citomegalovirus
|
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
EP2943221A1
(en)
|
2013-01-10 |
2015-11-18 |
Novartis AG |
Influenza virus immunogenic compositions and uses thereof
|
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
ES2774968T3
(es)
*
|
2013-12-19 |
2020-07-23 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
|
EP3798229A1
(en)
|
2014-03-25 |
2021-03-31 |
Yale University |
Uses of parasite macrophage migration inhibitory factors
|
|
EP3129008A4
(en)
|
2014-04-08 |
2017-09-06 |
Aradigm Corporation |
Liposomes that form drug nanocrystals after freeze-thaw
|
|
US9532986B2
(en)
|
2014-04-08 |
2017-01-03 |
Aradigm Corporation |
Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
EP2974739A1
(en)
|
2014-07-15 |
2016-01-20 |
Novartis AG |
RSVF trimerization domains
|
|
AU2015289583A1
(en)
|
2014-07-16 |
2017-02-02 |
Modernatx, Inc. |
Chimeric polynucleotides
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
US12150980B2
(en)
|
2015-07-30 |
2024-11-26 |
Modernatx, Inc. |
Concatemeric peptide epitope RNAs
|
|
WO2017049245A2
(en)
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
JP6991977B2
(ja)
*
|
2015-09-23 |
2022-02-03 |
マサチューセッツ インスティテュート オブ テクノロジー |
修飾デンドリマーナノ粒子ワクチン送達用組成物及び方法
|
|
CA3001003A1
(en)
|
2015-10-05 |
2017-04-13 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
EP3718565B1
(en)
|
2015-10-22 |
2022-04-27 |
ModernaTX, Inc. |
Respiratory virus vaccines
|
|
JP7080172B2
(ja)
|
2015-12-10 |
2022-06-03 |
モデルナティエックス インコーポレイテッド |
治療薬の送達のための組成物及び方法
|
|
ES2913626T5
(en)
|
2015-12-22 |
2025-05-12 |
Modernatx Inc |
Compounds and compositions for intracellular delivery of agents
|
|
WO2017123315A2
(en)
*
|
2016-01-12 |
2017-07-20 |
Aradigm Corporation |
Nanocrystals formed in a microenvironment
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
WO2017201340A2
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
|
US10967057B2
(en)
|
2016-06-02 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Zika viral antigen constructs
|
|
WO2017220099A1
(en)
|
2016-06-24 |
2017-12-28 |
Statens Serum Institut |
Adjuvants with modified drainage properties
|
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3538146A4
(en)
|
2016-11-11 |
2020-07-15 |
ModernaTX, Inc. |
INFLUENZA VACCINE
|
|
US11780885B2
(en)
|
2016-11-17 |
2023-10-10 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
JP7731656B2
(ja)
*
|
2017-02-01 |
2025-09-01 |
モデルナティエックス インコーポレイテッド |
Rna癌ワクチン
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
EP3596041B1
(en)
|
2017-03-15 |
2022-11-02 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
WO2018170336A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
JP7220154B2
(ja)
|
2017-03-15 |
2023-02-09 |
モデルナティエックス インコーポレイテッド |
アミノ脂質の結晶形態
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US11905525B2
(en)
|
2017-04-05 |
2024-02-20 |
Modernatx, Inc. |
Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
SG11201910101SA
(en)
|
2017-05-08 |
2019-11-28 |
Gritstone Oncology Inc |
Alphavirus neoantigen vectors
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
AU2018298422B2
(en)
|
2017-07-04 |
2023-04-06 |
CureVac SE |
Novel nucleic acid molecules
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP7275111B2
(ja)
*
|
2017-08-31 |
2023-05-17 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の生成方法
|
|
WO2019053012A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Rna Pharmaceuticals Gmbh |
RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS
|
|
US20200283497A1
(en)
|
2017-09-13 |
2020-09-10 |
Biontech Cell & Gene Therapies Gmbh |
Rna replicon for expressing at cell receptor or an artificial t cell receptor
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
US12036282B2
(en)
*
|
2017-12-06 |
2024-07-16 |
Newsouth Innovations Pty Limited |
Liposomal system for drug delivery
|
|
KR20200118029A
(ko)
|
2018-01-04 |
2020-10-14 |
아이코닉 테라퓨틱스, 인코포레이티드 |
항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
|
|
WO2020035609A2
(en)
|
2018-08-17 |
2020-02-20 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
JP7526168B2
(ja)
|
2018-09-19 |
2024-07-31 |
モデルナティエックス インコーポレイテッド |
Peg脂質及びそれらの使用
|
|
US12383508B2
(en)
|
2018-09-19 |
2025-08-12 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EA202190688A1
(ru)
|
2018-10-09 |
2021-06-07 |
Дзе Юниверсити Оф Бритиш Коламбиа |
Композиции и системы, содержащие трансфекционно-компетентные везикулы, не содержащие органических растворителей и детергентов, и связанные с ними способы
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
WO2020144295A1
(en)
|
2019-01-10 |
2020-07-16 |
Biontech Rna Pharmaceuticals Gmbh |
Localized administration of rna molecules for therapy
|
|
SG11202110623PA
(en)
*
|
2019-03-29 |
2021-10-28 |
Glycomine Inc |
Liposomal formulations, and methods of using and preparing thereof
|
|
CN114072516B
(zh)
|
2019-05-30 |
2025-01-14 |
磨石生物公司 |
经修饰的腺病毒
|
|
US20220233685A1
(en)
|
2019-06-18 |
2022-07-28 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
EP3986915A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Recombinant interleukin 12 construct and uses thereof
|
|
TW202114731A
(zh)
|
2019-06-18 |
2021-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
B型肝炎病毒(HBV)疫苗與靶向HBV之RNAi之組合
|
|
CA3143631A1
(en)
|
2019-06-20 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
CA3146900A1
(en)
|
2019-07-21 |
2021-01-28 |
Glaxosmithkline Biologicals Sa |
Therapeutic viral vaccine
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP3819377A1
(en)
|
2019-11-08 |
2021-05-12 |
Justus-Liebig-Universität Gießen |
Circular rna and uses thereof for inhibiting rna-binding proteins
|
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
Vaccines based on mutant calr and jak2 and their uses
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
EP3865122A1
(en)
*
|
2020-02-11 |
2021-08-18 |
Pantherna Therapeutics GmbH |
Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
|
|
WO2021183564A1
(en)
|
2020-03-09 |
2021-09-16 |
Arcturus Therapeutics, Inc. |
Compositions and methods for inducing immune responses
|
|
CN115667530A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒dna载体和其用于表达因子ix治疗剂的用途
|
|
US20230134550A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
US20230364219A1
(en)
|
2020-04-16 |
2023-11-16 |
Glaxosmithkline Biologicals Sa |
Sars cov-2 spike protein construct
|
|
CA3179444A1
(en)
*
|
2020-05-20 |
2021-11-25 |
Avak Kahvejian |
Immunogenic compositions and uses thereof
|
|
JP7769644B2
(ja)
|
2020-06-04 |
2025-11-13 |
バイオエヌテック エスエー |
多用途かつ効率的な遺伝子発現のためのrnaレプリコン
|
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
US20230256090A1
(en)
|
2020-06-29 |
2023-08-17 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
US12295997B2
(en)
|
2020-07-06 |
2025-05-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CA3188801A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
BR112023000327A2
(pt)
|
2020-07-16 |
2023-01-31 |
Acuitas Therapeutics Inc |
Lipídeos catiônicos para o uso em nanopartículas lipídicas
|
|
BR112023001648A2
(pt)
|
2020-07-27 |
2023-04-04 |
Anjarium Biosciences Ag |
Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
|
|
JP2023541108A
(ja)
|
2020-08-06 |
2023-09-28 |
グリットストーン バイオ インコーポレイテッド |
マルチエピトープワクチンカセット
|
|
JP2023537609A
(ja)
|
2020-08-14 |
2023-09-04 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
脂質ナノ粒子を凍結乾燥する方法
|
|
EP4008785A1
(en)
|
2020-12-03 |
2022-06-08 |
Justus-Liebig-Universität Gießen |
Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses
|
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
KR20230164648A
(ko)
|
2020-12-22 |
2023-12-04 |
큐어백 에스이 |
SARS-CoV-2 변이체에 대한 RNA 백신
|
|
US20240301006A1
(en)
|
2020-12-23 |
2024-09-12 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna
|
|
JP2024501022A
(ja)
|
2020-12-28 |
2024-01-10 |
アークトゥルス セラピューティクス, インコーポレイテッド |
Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen)
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
JP2024511206A
(ja)
|
2021-03-26 |
2024-03-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
|
CN115515926B
(zh)
*
|
2021-04-08 |
2023-10-20 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
KR20240012370A
(ko)
|
2021-04-20 |
2024-01-29 |
안자리움 바이오사이언시스 아게 |
아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
|
|
MX2023012643A
(es)
|
2021-04-27 |
2024-01-05 |
Generation Bio Co |
Vectores de adn no virales que expresan anticuerpos terapéuticos y usos de estos.
|
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
US20240285755A1
(en)
|
2021-05-24 |
2024-08-29 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
WO2022259191A1
(en)
|
2021-06-09 |
2022-12-15 |
Glaxosmithkline Biologicals Sa |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023021421A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
EP4387597A1
(en)
|
2021-08-16 |
2024-06-26 |
GlaxoSmithKline Biologicals SA |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
AU2022337090A1
(en)
|
2021-09-03 |
2024-02-15 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
CA3234396A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Modified replicable rna and related compositions and their use
|
|
JP2024539089A
(ja)
|
2021-10-18 |
2024-10-28 |
バイオエヌテック エスエー |
修飾複製可能rnaの機能および関連する組成物を増加させるための変異を決定する方法ならびにそれらの使用
|
|
KR20240107139A
(ko)
|
2021-11-08 |
2024-07-08 |
오나 테라퓨틱스, 인코포레이티드 |
원형 폴리뉴클레오티드를 전달하기 위한 지질 나노입자 조성물
|
|
KR20240123832A
(ko)
|
2021-12-16 |
2024-08-14 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자 제형에 사용하기 위한 지질
|
|
US20250381294A1
(en)
|
2022-01-14 |
2025-12-18 |
Anjarium Biosciences Ag |
Compositions of DNA Molecules Encoding Factor VIII, Methods of Making Thereof, and Methods of Use Thereof
|
|
KR20240161965A
(ko)
|
2022-03-14 |
2024-11-13 |
제너레이션 바이오 컴퍼니 |
이종 프라임 부스트 백신 조성물 및 사용 방법
|
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
EP4539876A2
(en)
|
2022-06-18 |
2025-04-23 |
GlaxoSmithKline Biologicals S.A. |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
EP4587579A1
(en)
|
2022-09-15 |
2025-07-23 |
BioNTech SE |
Systems and compositions comprising trans-amplifying rna vectors with mirna
|
|
KR20250075664A
(ko)
|
2022-09-26 |
2025-05-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
인플루엔자 바이러스 백신
|
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
TW202428289A
(zh)
|
2022-11-08 |
2024-07-16 |
美商歐納醫療公司 |
環狀rna組合物
|
|
KR20250129819A
(ko)
|
2022-12-01 |
2025-08-29 |
제너레이션 바이오 컴퍼니 |
핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
|
|
CN120641465A
(zh)
|
2022-12-01 |
2025-09-12 |
世代生物公司 |
新颖的聚甘油缀合脂质和包含其的脂质纳米颗粒组合物
|
|
KR20250114116A
(ko)
|
2022-12-01 |
2025-07-28 |
제너레이션 바이오 컴퍼니 |
세포 표적화를 위한 스텔스 지질 나노입자 조성물
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
CN120456919A
(zh)
|
2022-12-19 |
2025-08-08 |
葛兰素史克生物有限公司 |
乙型肝炎组合物
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
CN121001738A
(zh)
|
2023-04-27 |
2025-11-21 |
葛兰素史克生物有限公司 |
流感病毒疫苗
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
AU2024269222A1
(en)
|
2023-05-05 |
2025-10-09 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025040709A1
(en)
|
2023-08-24 |
2025-02-27 |
BioNTech SE |
Systems and compositions comprising highly active trans-amplifying replicases
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025051381A1
(en)
|
2023-09-08 |
2025-03-13 |
BioNTech SE |
Methods and compositions for localized expression of administered rna
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|